149 related articles for article (PubMed ID: 26451276)
41. (Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial.
Reni M; Dugnani E; Cereda S; Belli C; Balzano G; Nicoletti R; Liberati D; Pasquale V; Scavini M; Maggiora P; Sordi V; Lampasona V; Ceraulo D; Di Terlizzi G; Doglioni C; Falconi M; Piemonti L
Clin Cancer Res; 2016 Mar; 22(5):1076-85. PubMed ID: 26459175
[TBL] [Abstract][Full Text] [Related]
42. Gemcitabine/nab-paclitaxel as second-line therapy following FOLFIRINOX in metastatic/advanced pancreatic cancer-retrospective analysis of response.
Nguyen KT; Kalyan A; Beasley HS; Singhi AD; Sun W; Zeh HJ; Normolle D; Bahary N
J Gastrointest Oncol; 2017 Jun; 8(3):556-565. PubMed ID: 28736642
[TBL] [Abstract][Full Text] [Related]
43.
Kim G
Cancer Manag Res; 2017; 9():85-96. PubMed ID: 28356771
[TBL] [Abstract][Full Text] [Related]
44. Comparison of treatment patterns, resource utilization, and cost of care in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine or FOLFIRINOX.
Kim GP; Parisi MF; Patel MB; Pelletier CL; Belk KW
Expert Rev Clin Pharmacol; 2017 May; 10(5):559-565. PubMed ID: 28286977
[TBL] [Abstract][Full Text] [Related]
45.
Tabernero J; Kunzmann V; Scheithauer W; Reni M; Shiansong Li J; Ferrara S; Djazouli K
Onco Targets Ther; 2017; 10():591-596. PubMed ID: 28203092
[TBL] [Abstract][Full Text] [Related]
46. [Nab-Paclitaxel plus Gemcitabine for Metastatic Pancreatic Cancer].
Katsura Y; Takeda Y; Ohmura Y; Motoyama Y; Ishida T; Morimoto Y; Matsushita K; Naito A; Murakami K; Kagawa Y; Okishiro M; Takeno A; Egawa C; Kato T; Tamura S
Gan To Kagaku Ryoho; 2015 Nov; 42(12):2367-9. PubMed ID: 26805366
[TBL] [Abstract][Full Text] [Related]
47. Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas.
Ramanathan RK; Goldstein D; Korn RL; Arena F; Moore M; Siena S; Teixeira L; Tabernero J; Van Laethem JL; Liu H; McGovern D; Lu B; Von Hoff DD
Ann Oncol; 2016 Apr; 27(4):648-53. PubMed ID: 26802153
[TBL] [Abstract][Full Text] [Related]
48. Prognostic and predictive markers in pancreatic adenocarcinoma.
Le N; Sund M; Vinci A;
Dig Liver Dis; 2016 Mar; 48(3):223-30. PubMed ID: 26769569
[TBL] [Abstract][Full Text] [Related]
49. Patients with Advanced Pancreatic Cancer and Hyperbilirubinaemia: Review and German Expert Opinion on Treatment with nab-Paclitaxel plus Gemcitabine.
Vogel A; Kullmann F; Kunzmann V; Al-Batran SE; Oettle H; Plentz R; Siveke J; Springfeld C; Riess H
Oncol Res Treat; 2015; 38(11):596-603. PubMed ID: 26599274
[TBL] [Abstract][Full Text] [Related]
50. Pancreatic cancer and SBRT: A new potential option?
Hajj C; Goodman KA
Rep Pract Oncol Radiother; 2015; 20(5):377-84. PubMed ID: 26549996
[TBL] [Abstract][Full Text] [Related]
51. Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer.
Wu Z; Gabrielson A; Hwang JJ; Pishvaian MJ; Weiner LM; Zhuang T; Ley L; Marshall JL; He AR
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1309-14. PubMed ID: 26507197
[TBL] [Abstract][Full Text] [Related]
52. Phase II trial of selective internal radiation therapy and systemic chemotherapy for liver-predominant metastases from pancreatic adenocarcinoma.
Gibbs P; Do C; Lipton L; Cade DN; Tapner MJ; Price D; Bower GD; Dowling R; Lichtenstein M; van Hazel GA
BMC Cancer; 2015 Oct; 15():802. PubMed ID: 26503593
[TBL] [Abstract][Full Text] [Related]
53. Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-naïve non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenocarcinoma or mutated EGFR.
Choi YJ; Lee DH; Choi CM; Lee JS; Lee SJ; Ahn JH; Kim SW
BMC Cancer; 2015 Oct; 15():763. PubMed ID: 26493267
[TBL] [Abstract][Full Text] [Related]
54. Preoperative Diagnostic Angiogram and Endovascular Aortic Stent Placement for Appleby Resection Candidates: A Novel Surgical Technique in the Management of Locally Advanced Pancreatic Cancer.
Trabulsi N; Pelletier JS; Abraham C; Vanounou T
HPB Surg; 2015; 2015():523273. PubMed ID: 26491217
[TBL] [Abstract][Full Text] [Related]
55. A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors.
McRee AJ; Sanoff HK; Carlson C; Ivanova A; O'Neil BH
Invest New Drugs; 2015 Dec; 33(6):1225-31. PubMed ID: 26490655
[TBL] [Abstract][Full Text] [Related]
56. Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study.
Lee SJ; Kim S; Kim M; Lee J; Park YH; Im YH; Park SH
BMC Cancer; 2015 Oct; 15():693. PubMed ID: 26468007
[TBL] [Abstract][Full Text] [Related]
57. Tolerability of Gemcitabine Plus Cisplatin for Treatment of Urothelial Cancer in the Elderly Population.
Jan AS; Dolan DE; Lombardi K; Gupta S
Clin Genitourin Cancer; 2016 Jun; 14(3):e257-63. PubMed ID: 26462439
[TBL] [Abstract][Full Text] [Related]
58. Combinatorial treatment of CD95L and gemcitabine in pancreatic cancer cells induces apoptotic and RIP1-mediated necroptotic cell death network.
Pietkiewicz S; Eils R; Krammer PH; Giese N; Lavrik IN
Exp Cell Res; 2015 Nov; 339(1):1-9. PubMed ID: 26453936
[TBL] [Abstract][Full Text] [Related]
59. Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis.
Chae H; Jeong H; Cheon J; Chon HJ; Ryu H; Kim IH; Kang MJ; Jeong JH; Ryoo BY; Kim KP; Yoo C
Ther Adv Med Oncol; 2020; 12():1758835920923424. PubMed ID: 32523632
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
